Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1.
Immunol Res
; 58(1): 139-53, 2014 Jan.
Article
en En
| MEDLINE
| ID: mdl-23666811
ABSTRACT
Defensins display immunostimulatory activities including a chemotactic effect for T lymphocytes/immature dendritic cells and secretion of pro-inflammatory cytokines suggest their role in bridging innate and adaptive immunity. We hypothesized whether defensins with separately emulsified HIV-1 immunogen would elicit peptide-specific systemic and mucosal antibody response in mice. The HIV-1 peptide alone in microsphere showed low peptide-specific antibody response in sera and different washes, while the presence of defensins markedly increased the antibody peak titre both in sera (102,400-409,600) (p < 0.05) and in washes (800-25,600) (p < 0.001). Defensins with HIV-1 peptide were showing 43.0-83.2% and 38.7-72.3% in vitro neutralization against laboratory isolates in serum and lavage samples, respectively, higher than HIV-1 peptide alone. Our findings may have implications in the development of new mucosal adjuvant for AIDS vaccination.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proteína gp41 de Envoltorio del VIH
/
Infecciones por VIH
/
VIH-1
/
Vacunas contra el SIDA
/
Inmunidad Mucosa
/
Defensinas
Límite:
Animals
Idioma:
En
Año:
2014
Tipo del documento:
Article